Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

ALAMEDA, Calif. , Aug. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Growth Conference on Tuesday, August 13, 2024.

Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View

While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say

Penumbra, Inc. (NYSE:PEN ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Michael Sarcone - Jefferies Pito Chickering - Deutsche Bank Richard Newitter - Truist Securities Operator Good afternoon. My name is Aaron, and I will be your conference operator for today.

Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript

Penumbra (PEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.43 per share a year ago.

Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates

ALAMEDA, Calif. , July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024.

Penumbra, Inc. Reports Second Quarter 2024 Financial Results

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Penumbra (PEN) is a Strong Growth Stock

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice

The consensus price target hints at a 34.2% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Penumbra (PEN)? Wall Street Analysts Think 34.22%

ALAMEDA, Calif. , July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024

Enovis Corp

Repligen

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Blast Off In June

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?

ALAMEDA, Calif. , June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024.

Penumbra, Inc. to Present at the Truist Securities MedTech Conference

ALAMEDA, Calif. , May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, June 6, 2024.

Penumbra, Inc. to Present at the William Blair Growth Stock Conference

Globus Medical

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

GMED or PEN: Which Is the Better Value Stock Right Now?

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

Penumbra, Inc. (NYSE:PEN ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - President, Chairman and CEO Maggie Yuen - CFO Jason Mills - Executive Vice President of Strategy Conference Call Participants Margaret Kaczor - William Blair Joanne Wuensch - Citi William Plovanic - Canaccord Genuity Fund Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies David Rescott - Baird Michael Matson - Needham & Company Shagun Singh Chadha - RBC Capital Markets Operator Good afternoon. My name is Ellie and I will be your conference operator for today.

Penumbra, Inc. (PEN) Q1 2024 Earnings Call Transcript

ALAMEDA, Calif. , May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024.

Penumbra, Inc. Reports First Quarter 2024 Financial Results

Ligand Pharmaceuticals

Oscar Health

Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.

Don't Overlook These Top Medical Stocks as Q1 Earnings Approach

ALAMEDA, Calif. , May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.

Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.

News for Penumbra Stock (PEN)